SCYNEXIS, Inc. (SCYX): Price and Financial Metrics

SCYNEXIS, Inc. (SCYX): $1.67

-0.15 (-8.24%)

POWR Rating

Component Grades














  • Growth is the dimension where SCYX ranks best; there it ranks ahead of 85.81% of US stocks.
  • The strongest trend for SCYX is in Growth, which has been heading up over the past 177 days.
  • SCYX ranks lowest in Quality; there it ranks in the 0th percentile.

SCYX Stock Summary

  • SCYX's price/sales ratio is 14.67; that's higher than the P/S ratio of 92.99% of US stocks.
  • Revenue growth over the past 12 months for SCYNEXIS INC comes in at -66.86%, a number that bests merely 2.91% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SCYX comes in at -135.54% -- higher than that of only 4.43% of stocks in our set.
  • Stocks that are quantitatively similar to SCYX, based on their financial statements, market capitalization, and price volatility, are NURO, BKYI, WPRT, CTSO, and KMDA.
  • SCYX's SEC filings can be seen here. And to visit SCYNEXIS INC's official web site, go to

SCYX Valuation Summary

  • In comparison to the median Healthcare stock, SCYX's price/sales ratio is 673.68% higher, now standing at 14.7.
  • Over the past 108 months, SCYX's price/sales ratio has gone up 10.2.

Below are key valuation metrics over time for SCYX.

Stock Date P/S P/B P/E EV/EBIT
SCYX 2023-03-24 14.7 3.6 -0.8 -0.5
SCYX 2023-03-23 14.1 3.4 -0.8 -0.5
SCYX 2023-03-22 15.7 3.8 -0.8 -0.6
SCYX 2023-03-21 12.2 3.0 -0.7 -0.4
SCYX 2023-03-20 9.0 2.2 -0.5 -0.2
SCYX 2023-03-17 9.0 2.2 -0.5 -0.2

SCYX Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -36.6%.
  • Its year over year cash and equivalents growth rate is now at 3.41%.
  • Its 4 year net cashflow from operations growth rate is now at -68.14%.
SCYX's revenue has moved up $4,043,000 over the prior 33 months.

The table below shows SCYX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 4.164 -82.597 -77.623
2022-06-30 3.123 -76.675 -48.644
2022-03-31 1.8 -69.789 -33.641
2021-12-31 13.163 -54.56 -32.866
2021-09-30 12.566 -45.612 -46.334
2021-06-30 12.05 -38.895 -44.82

SCYX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SCYX has a Quality Grade of C, ranking ahead of 29.3% of graded US stocks.
  • SCYX's asset turnover comes in at 0.134 -- ranking 232nd of 682 Pharmaceutical Products stocks.
  • ACER, QURE, and MNOV are the stocks whose asset turnover ratios are most correlated with SCYX.

The table below shows SCYX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.134 1 -3.908
2021-03-31 0.169 1 -5.208
2020-12-31 0.000 NA -3.192
2020-09-30 0.000 NA -1.322
2020-06-30 0.000 NA -1.486
2020-03-31 0.001 1 -1.353

SCYX Price Target

For more insight on analysts targets of SCYX, see our SCYX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.36 Average Broker Recommendation 1.36 (Strong Buy)

SCYX Stock Price Chart Interactive Chart >

Price chart for SCYX

SCYX Price/Volume Stats

Current price $1.67 52-week high $4.40
Prev. close $1.82 52-week low $1.15
Day low $1.60 Volume 212,600
Day high $1.85 Avg. volume 419,068
50-day MA $1.60 Dividend yield N/A
200-day MA $2.09 Market Cap 54.54M

SCYNEXIS, Inc. (SCYX) Company Bio

SCYNEXIS, Inc., a pharmaceutical company, develops and commercializes novel anti-infectives to address unmet therapeutic needs. Its lead product candidate includes SCY-078, which is in Phase I clinical trials of the intravenous formulation; Phase II clinical trials for the treatment of invasive candida infections; and Phase II clinical trials for unmet medical needs, such as vulvovaginal candidiasis. The company was founded in 1999 and is based in Jersey City, New Jersey.

SCYX Latest News Stream

Event/Time News Detail
Loading, please wait...

SCYX Latest Social Stream

Loading social stream, please wait...

View Full SCYX Social Stream

Latest SCYX News From Around the Web

Below are the latest news stories about SCYNEXIS INC that investors may wish to consider to help them evaluate SCYX as an investment opportunity.

CDC Rings Alarm About Deadly Fungus. 6 Things to Know.

The number of infections from the Candida Auris fungus, which can be deadly for people who are already sick, is small but rapidly growing.

Yahoo | March 22, 2023

SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some losses

Some of the losses seen by insiders who purchased US$236k worth of SCYNEXIS, Inc. ( NASDAQ:SCYX ) shares over the past...

Yahoo | March 22, 2023

Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock

Guggenheim has initiated coverage on SCYNEXIS Inc (NASDAQ: SCYX) with a Buy rating and a price target of $8. The anti-infectives space remains out of favor with investors, but SCYNEXIS offers a unique opportunity given that ibrexafungerp is already approved to treat vulvovaginal candidiasis (VVC), and has shown promising early data against more severe invasive infections, writes the analyst. In October, SCYNEXIS announced a new strategic direction to refocus its resources on the clinical develop

Yahoo | March 1, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday!

William White on InvestorPlace | February 6, 2023

SCYNEXIS (NASDAQ:SCYX) shareholders are up 14% this past week, but still in the red over the last five years

It's nice to see the SCYNEXIS, Inc. ( NASDAQ:SCYX ) share price up 14% in a week. But that doesn't change the fact that...

Yahoo | January 14, 2023

Read More 'SCYX' Stories Here

SCYX Price Returns

1-mo 12.08%
3-mo 7.05%
6-mo -30.42%
1-year -58.46%
3-year -77.31%
5-year -87.54%
YTD 7.05%
2022 -74.43%
2021 -20.26%
2020 -15.93%
2019 89.58%
2018 -79.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.887 seconds.